Q: In Donville's most recent ROE reporter, he notes that he remains committed to Concordia. He says this:
"...at current valuations, I think the company is
worth a lot more than $50 a share. On our numbers, CXR trades on 4.8x 2016 Cash Earnings and 1.1x BVPS, while earning a 24% ROE."
Are these valuations in line with 5i's research, including the AmCo (Amphidarm) deal?
"...at current valuations, I think the company is
worth a lot more than $50 a share. On our numbers, CXR trades on 4.8x 2016 Cash Earnings and 1.1x BVPS, while earning a 24% ROE."
Are these valuations in line with 5i's research, including the AmCo (Amphidarm) deal?